Dr. Mark Souweidane

A Phase I clinical trial demonstrated that a targeted approach to treating a deadly brain tumor in children called diffuse intrinsic pontine glioma (DIPG) is safe, reported Weill Cornell Medicine and Memorial Sloan Kettering Cancer Center investigators.

Weill Cornell Medicine faculty members and alumni were honored with awards for their exemplary achievements in research, education and patient care during the institution’s commencement activities on May 15 and 16.

Surgery can usually be avoided in children with a rare tumor of the skull, based on new research by investigators from Weill Cornell Medicine, NewYork-Presbyterian, Nicklaus Children’s Hospital, the University of Texas Southwestern, the University of British Columbia and McGovern Medical School.    

Diffuse Intrinsic Pontine Glioma (DIPG) is every parent’s worst nightmare: a rare and incurable type of brain cancer that affects young children. Dr. Mark Souweidane decided to make curing this cancer his “Holy Grail”—and his progress since then has been impressive.